Health Technology · Pharmaceuticals: Major · NSE: FREDUN · data 2026-10-09
Fredun Pharmaceuticals Ltd.
Health check: Strong (6.9/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹1,552.3
Market cap
₹2,537 cr
P/E
56.4
P/B
—
ROE
15.6%
ROCE
33.0%
Debt / equity
0.87
Dividend yield
0.02%
1-year return
0.8%
52-week high
₹1,665
52-week low
₹1,195.2
Operating margin
13.4%
Growth
| Revenue (last 12 months) | ₹748 cr |
| Net profit (last 12 months) | ₹44 cr |
| Sales growth, 3 years (yearly) | 32.5% |
| Profit growth, 3 years (yearly) | 44.5% |
Similar companies
Hikal Limited (HIKAL) · Alembic Limited (ALEMBICLTD) · Dishman Carbogen Amcis Ltd. (DCAL) · Venus Remedies Limited (VENUSREM) · Syncom Formulation (India) Ltd. (SYNCOMF)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open FREDUN in NSE Scanner →